First Trust Advisors LP Sells 211,346 Shares of Iqvia Holdings Inc (NYSE:IQV)

First Trust Advisors LP cut its stake in Iqvia Holdings Inc (NYSE:IQV) by 21.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 782,862 shares of the medical research company’s stock after selling 211,346 shares during the quarter. First Trust Advisors LP owned about 0.40% of Iqvia worth $116,944,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. CWM LLC increased its holdings in Iqvia by 63.4% during the 2nd quarter. CWM LLC now owns 165 shares of the medical research company’s stock worth $27,000 after purchasing an additional 64 shares during the period. Montag & Caldwell LLC grew its holdings in shares of Iqvia by 2.4% during the second quarter. Montag & Caldwell LLC now owns 2,750 shares of the medical research company’s stock valued at $442,000 after purchasing an additional 64 shares during the last quarter. Archford Capital Strategies LLC grew its holdings in shares of Iqvia by 1.8% during the second quarter. Archford Capital Strategies LLC now owns 3,877 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 67 shares during the last quarter. Securian Asset Management Inc grew its holdings in shares of Iqvia by 0.4% during the second quarter. Securian Asset Management Inc now owns 16,442 shares of the medical research company’s stock valued at $2,646,000 after purchasing an additional 68 shares during the last quarter. Finally, Capital Investment Advisory Services LLC grew its holdings in shares of Iqvia by 46.0% during the second quarter. Capital Investment Advisory Services LLC now owns 219 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 69 shares during the last quarter. Institutional investors own 89.92% of the company’s stock.

Several equities analysts have recently commented on the company. Wells Fargo & Co upped their target price on Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Credit Suisse Group upped their target price on Iqvia from $165.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Barclays set a $180.00 price objective on Iqvia and gave the company a “buy” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. increased their price objective on Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a research report on Thursday, July 25th. Finally, ValuEngine downgraded Iqvia from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $166.46.

Shares of NYSE:IQV traded down $0.25 on Friday, reaching $137.59. 1,450,481 shares of the company traded hands, compared to its average volume of 1,291,668. Iqvia Holdings Inc has a fifty-two week low of $104.90 and a fifty-two week high of $164.13. The company’s 50 day moving average is $147.15 and its 200-day moving average is $148.22. The stock has a market capitalization of $27.14 billion, a PE ratio of 26.87, a P/E/G ratio of 1.55 and a beta of 0.87. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.14.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.76 billion. During the same quarter in the prior year, the firm earned $1.42 EPS. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. As a group, analysts expect that Iqvia Holdings Inc will post 5.9 EPS for the current year.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: What is a stock portfolio tracker?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply